Insmed (NASDAQ:INSM) Price Target Raised to $196.00 at The Goldman Sachs Group

Key Points

• The Goldman Sachs Group raised Insmed's price target from $121.00 to $196.00, reflecting a potential upside of 25.52% from its current stock price, and maintains a "buy" rating.
• Insmed reported a net loss of $1.70 per share for the latest quarter, which was below analysts' expectations, though the company saw an 18.9% increase in quarterly revenue year-over-year.
• Insider selling has been notable, with significant shares sold by COO Roger Adsett and another insider, indicating potential shifts in confidence among company executives.

Insmed (NASDAQ:INSM - Get Free Report) had its price target hoisted by equities research analysts at The Goldman Sachs Group from $121.00 to $196.00 in a report released on Friday,Benzinga reports. The brokerage presently has a "buy" rating on the biopharmaceutical company's stock. The Goldman Sachs Group's price objective would suggest a potential upside of 25.52% from the company's current price.

INSM has been the subject of several other research reports. Evercore ISI restated an "outperform" rating and set a $180.00 target price on shares of Insmed in a research report on Wednesday. Stifel Nicolaus raised their target price on Insmed from $121.00 to $145.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. Morgan Stanley raised their target price on Insmed from $126.00 to $144.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 21st. Citigroup upgraded Insmed to a "buy" rating in a research report on Tuesday, June 10th. Finally, UBS Group raised their target price on Insmed from $124.00 to $133.00 and gave the stock a "buy" rating in a research report on Friday, August 8th. Nineteen equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $149.06.

Insmed Stock Performance

Shares of NASDAQ:INSM traded up $3.35 during trading on Friday, hitting $156.15. 1,242,290 shares of the stock were exchanged, compared to its average volume of 2,723,624. Insmed has a 1-year low of $60.40 and a 1-year high of $157.89. The company has a market capitalization of $33.01 billion, a price-to-earnings ratio of -27.45 and a beta of 1.03. The company's fifty day simple moving average is $131.39 and its 200-day simple moving average is $98.41. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. During the same period in the previous year, the business posted ($1.94) EPS. Insmed's revenue for the quarter was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. Sell-side analysts expect that Insmed will post -4.56 EPS for the current fiscal year.

Insider Transactions at Insmed

In other news, insider Michael Alexander Smith sold 24,272 shares of the business's stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $143.89, for a total transaction of $3,492,498.08. Following the completion of the sale, the insider owned 54,902 shares in the company, valued at $7,899,848.78. The trade was a 30.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Roger Adsett sold 25,000 shares of the business's stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $127.58, for a total value of $3,189,500.00. Following the sale, the chief operating officer owned 105,637 shares of the company's stock, valued at approximately $13,477,168.46. The trade was a 19.14% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 277,332 shares of company stock worth $33,842,327. 3.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Insmed

Institutional investors and hedge funds have recently made changes to their positions in the company. Teachers Retirement System of The State of Kentucky bought a new stake in shares of Insmed during the first quarter worth $975,000. OneDigital Investment Advisors LLC raised its position in shares of Insmed by 47.1% during the first quarter. OneDigital Investment Advisors LLC now owns 5,226 shares of the biopharmaceutical company's stock worth $399,000 after acquiring an additional 1,673 shares during the last quarter. Caxton Associates LLP bought a new stake in shares of Insmed during the first quarter worth $441,000. Sowell Financial Services LLC bought a new stake in shares of Insmed during the first quarter worth $255,000. Finally, Assenagon Asset Management S.A. increased its holdings in Insmed by 84.5% in the second quarter. Assenagon Asset Management S.A. now owns 73,404 shares of the biopharmaceutical company's stock valued at $7,387,000 after purchasing an additional 33,626 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.